Value of Comprehensive Geriatric Assessment, clinical judgment, and performance status in the treatment of patients with epithelal ovarian carcinoma aged 70 years and older.

1. Histological confirmed (extra) epithelial ovarian carcinoma FIGO IIB - IV. Tumors of borderline malignancy are excluded;

2. No prior treatment with cytostatic agents or radiotherapy;

3. Age ¡Ý 70 years;

4. Performance status 0-2;

5. Life expectancy ¡Ý 3 months;

6. Able to undergo protocol treatment according to clinical judgment of the medical oncologist;

7. No second primary malignancy except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin, or a prior cancer cured with surgery alone and with a disease-free interval of longer than 5 years;

8. Adequate hematological, renal and hepatic function as defined by the following required laboratory values (obtained ¡Ü 14 days prior to study enrollment):

a. WBC ¡Ý 3.0x109/L;

b. Platelets ¡Ý 100x109/L;

c. Calculated creatinine clearance ¡Ý 40 ml/min (according to the Cockroft and Gault formula), see 9.3;

d. Serum bilirubin ¡Ü 1.5 x upper normal limit;

e. SGOT (AST) and/or SGPT (ALT) ¡Ü 2.5 x upper normal limit;

9. Absence of significant cardiac disease, i.e. uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous year, or cardiac ventricular arrhythmias requiring medication. History of 2nd and 3rd degree heart blocks without pacemaker in situ;

10. No active infection, major medical illness, signs or symptoms of CNS involvement or leptomeningeal disease;

11. No known hypersensitivity reactions to any of the components of the treatment, including cremophor;

12. Absence of CTC grade ¡Ý 1 peripheral neurotoxicity;

13. Assessable for treatment and follow-up;

14. Informed consent.

No exclusion criteria mentioned in the protocol.